文献速递造血干细胞移植与细胞治疗白血病

低剂量抗胸腺细胞球蛋白预防HLA相合同胞移植慢性GVHD的随机研究

Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
PubMed 文献 · Am J Hematol · 2021-08-27

该前瞻性单中心开放标签随机研究纳入120例急性白血病患者,1:1随机接受低剂量兔抗胸腺细胞球蛋白(2.5 mg/kg)预防慢性GVHD。中位随访27个月,ATG组慢性GVHD累积发生率显著低于非ATG组(25.0% vs 65.4%,p<0.001),但复发率有升高趋势(20.0% vs 9.3%,p=0.055),高危细胞遗传学亚组复发风险显著增加。

要点

  • 低剂量ATG(2.5 mg/kg)可显著降低HLA相合同胞移植后慢性GVHD发生率。
  • ATG组复发率有升高趋势,高危细胞遗传学亚组复发风险显著增加。
  • ATG组EBV再激活率较高,无慢性GVHD无复发生存有改善趋势。

核心结论

  • 低剂量兔抗胸腺细胞球蛋白可有效预防HLA相合同胞移植后慢性GVHD,改善生活质量及无慢性GVHD无复发生存,但高危急性白血病患者需谨慎。

研究设计与样本

  • 前瞻性、单中心、开放标签、随机对照研究,纳入120例急性白血病患者,1:1随机分配至ATG组(2.5 mg/kg)或非ATG组。

主要发现

  • 中位随访27个月,慢性GVHD累积发生率ATG组25.0% vs 非ATG组65.4%(p<0.001)。
  • 复发率ATG组20.0% vs 非ATG组9.3%(p=0.055);高危细胞遗传学亚组29.6% vs 9.3%(p=0.042),非高危亚组12.2% vs 9.2%(p=0.596)。
  • 无慢性GVHD无复发生存ATG组46.7% vs 非ATG组19.4%(p=0.070);非高危亚组45.5% vs 0%(p=0.038)。
  • EBV再激活率ATG组21.8% vs 非ATG组5.1%(p=0.013),其他并发症无组间差异。
  • 移植后12个月ATG组生活质量评分中躯体成分改善。

关键数值与推荐

  • 低剂量兔抗胸腺细胞球蛋白剂量为2.5 mg/kg。
  • 慢性GVHD累积发生率25.0% vs 65.4%(p<0.001)。
  • 高危细胞遗传学亚组复发率29.6% vs 9.3%(p=0.042)。

临床怎么用

  • 对于HLA相合同胞移植的急性白血病患者,可考虑低剂量ATG预防慢性GVHD,但高危细胞遗传学患者需权衡复发风险。
  • ATG组EBV再激活率较高,需加强监测。

局限性

  • 单中心、开放标签研究,样本量120例,随访时间27个月。
  • 复发率差异仅为边缘显著(p=0.055),无慢性GVHD无复发生存差异未达统计学显著(p=0.070)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the proven efficacy of anti-T-cell or antithymocyte globulin (ATG) for chronic graft-versus-host disease (GVHD) prevention in transplantation from an unrelated donor, dosing protocols and the effects of ATG on relapse and infection remain controversial. In the setting of transplantation from an HLA-matched sibling (MSD-T), few randomized studies have been conducted. We conducted a prospective, single-center, open-label, randomized study of low-dose thymoglobulin (2.5 mg/kg) for chronic GVHD prevention. A total of 120 patients with acute leukemia were randomly assigned in a 1:1 ratio. After a median follow-up of 27 months, the cumulative incidence of chronic GVHD in the ATG and non-ATG groups was 25.0% and 65.4% (p < 0.001), respectively. The ATG group had an increased relapse rate compared with the non-ATG-group (20.0% vs. 9.3%; p = 0.055), with risks that differed according to cytogenetic subgroup (high-risk, 29.6% vs. 9.3%, p = 0.042; non-high-risk, 12.2% vs. 9.2%, p = 0.596). Chronic GVHD-free and relapse-free survival (cGRFS) was higher in the ATG group (46.7% vs. 19.4%; p = 0.070), and the difference was significant in a cytogenetic non-high-risk subgroup (45.5% vs. 0%; p = 0.038). No differences were observed in other survival outcomes. Improved physical components in quality-of-life scores were observed in the ATG group at 12 months after transplantation. A higher rate of Epstein-Barr virus reactivation was observed in the ATG group (21.8% vs. 5.1%; p = 0.013), whereas no between-group differences for other complications. In conclusion, the low-dose thymoglobulin effectively prevented chronic GVHD in MSD-T, resulting in improvement in quality-of-life and cGRFS, whereas the necessity of caution for high-risk acute leukemia.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cho BS, Min GJ, Park SS, et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. Am J Hematol. 2021. PMID: 34390504. doi:10.1002/ajh.26320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。